EU pharma sector enquiry slammed
16 April 2009
James Nurton, Cambridge
The European Commission’s pharmaceutical sector enquiry could have “a chilling effect on innovation in Europe” if the preliminary report is carried through into its final version, according to a pharmaceutical company executive
Speaking during the Fordham IP Conference in Cambridge, UK, David Rosenberg of GlaxoSmithKline’s IP department said the preliminary report presented a flawed understanding of the patent system and its relation to pharmaceutical innovation.
He said many of the statistics in the report were simplistic, while others were meaningless. Definitions were unclear and the report as a whole showed an “incomplete understanding” of the patent and research process.
He...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial